3D Protein Structure Predictions Made by an AI can Boost Cancer Research and Drug Discovery

In a living being, proteins make up roughly everything: from the molecular machines running every cell's metabolism, to the tip of your hair. Encoded in the DNA, a protein may be represented as a thread of hundreds of individual molecules called amino acids, linked together. Depending on its particular amino acids combination, a protein folds in one way or another, resulting in a functional 3D shape. The shape makes the function, and with 20 different amino acids available, the possible combinations are countless.

Current genomic technologies make it very easy to know the amino acid sequence of a protein but knowing its 3D shape demands for expensive and time-consuming experimental procedures, not always successful. For decades, researchers have tried to understand what makes a protein fold in a particular shape, to predict it from its amino acid sequence.

Alpha Fold 2 is a neural network developed by Deep Mind, a Google-owned Artificial Intelligence company, specifically trained to solve the 3D structure of proteins precisely from its amino acid sequence. Its accuracy impressed the scientific community a few years ago after its victories at the annual international contest on protein structure modelling CASP, when its team presented the full proteome for 11 different species, including humans.

To put all the data released by Alpha Fold 2 into context (over 300k models and growing), a community of independent researchers including Dr. Eduard Porta, head of the Cancer Immunogenetics group at the Josep Carreras Leukaemia Research Institute, compared the new structures made available to the currently available and concluded that Alpha Fold 2 contributed with an extra 25% of high-quality protein structures to any given species. Their analysis has been recently published at the prestigious journal Nature Structural Biology.

The key role that many proteins play in disease, such as cancer, is already known, but the lack of a deep knowledge of their functioning at the molecular level prevents the development of specific strategies against them. The structural information of these proteins will help scientists to understand those proteins much better, to know what other molecules they may interact with inside the cell and to design new drugs, capable of interfering with their function when they are altered.

There are limitations, of course, to the capabilities of Alpha Fold 2. The community team found the algorithm has problems when trying to recreate protein complexes. Most proteins work together with other proteins to get a biological function done, so predicting how different proteins could stick together would be highly desirable. Another limitation identified is its inability to show the structure of mutated proteins, with altered amino acids on its sequence. Mutations often result in abnormal protein function and are the cause of many diseases like cancer.

Despite its limitations, however, the team recognizes the outstanding contribution of Alpha Fold 2 to the community, that will impact basic and biomedical research greatly in the coming years. Not only thanks to its direct contribution (thousands of new reliable 3D protein models), but by starting a new era of computational tools based on artificial intelligence able to yield results that no one can anticipate.

As a matter of fact, this era has already started and, recently, a team at Meta (formerly Facebook) has used a modified version of its natural language predictor to "autocomplete" proteins. This AI tool, called ESMFold, seems to be less accurate compared to its Google's counterpart, but is 60 times faster and can overcome some of the identified Alpha Fold 2 limitations like handling mutated sequences.

All in all, as the authors of the publication admit, "the application of AlphaFold2 [and the coming tools] will have a transformative impact in life sciences."

Akdel M, Pires DEV, Pardo EP, Jänes J, Zalevsky AO, Mészáros B, Bryant P, Good LL, Laskowski RA, Pozzati G, Shenoy A, Zhu W, Kundrotas P, Serra VR, Rodrigues CHM, Dunham AS, Burke D, Borkakoti N, Velankar S, Frost A, Basquin J, Lindorff-Larsen K, Bateman A, Kajava AV, Valencia A, Ovchinnikov S, Durairaj J, Ascher DB, Thornton JM, Davey NE, Stein A, Elofsson A, Croll TI, Beltrao P.
A structural biology community assessment of AlphaFold2 applications.
Nat Struct Mol Biol. 2022 Nov 7. doi: 10.1038/s41594-022-00849-w

Most Popular Now

Unlocking the 10 Year Health Plan

The government's plan for the NHS is a huge document. Jane Stephenson, chief executive of SPARK TSL, argues the key to unlocking its digital ambitions is to consider what it...

Alcidion Grows Top Talent in the UK, wit…

Alcidion has today announced the addition of three new appointments to their UK-based team, with one internal promotion and two external recruits. Dr Paul Deffley has been announced as the...

AI can Find Cancer Pathologists Miss

Men assessed as healthy after a pathologist analyses their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to...

New Training Year Starts at Siemens Heal…

In September, 197 school graduates will start their vocational training or dual studies in Germany at Siemens Healthineers. 117 apprentices and 80 dual students will begin their careers at Siemens...

AI, Full Automation could Expand Artific…

Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review...

How AI could Speed the Development of RN…

Using artificial intelligence (AI), MIT researchers have come up with a new way to design nanoparticles that can more efficiently deliver RNA vaccines and other types of RNA therapies. After training...

MIT Researchers Use Generative AI to Des…

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). Using generative AI algorithms, the research...

AI Hybrid Strategy Improves Mammogram In…

A hybrid reading strategy for screening mammography, developed by Dutch researchers and deployed retrospectively to more than 40,000 exams, reduced radiologist workload by 38% without changing recall or cancer detection...

Penn Developed AI Tools and Datasets Hel…

Doctors treating kidney disease have long depended on trial-and-error to find the best therapies for individual patients. Now, new artificial intelligence (AI) tools developed by researchers in the Perelman School...

Are You Eligible for a Clinical Trial? C…

A new study in the academic journal Machine Learning: Health discovers that ChatGPT can accelerate patient screening for clinical trials, showing promise in reducing delays and improving trial success rates. Researchers...

Global Study Reveals How Patients View M…

How physicians feel about artificial intelligence (AI) in medicine has been studied many times. But what do patients think? A team led by researchers at the Technical University of Munich...

New AI Tool Addresses Accuracy and Fairn…

A team of researchers at the Icahn School of Medicine at Mount Sinai has developed a new method to identify and reduce biases in datasets used to train machine-learning algorithms...